Kestra Medical Technologies (NASDAQ:KMTS) Research Coverage Started at Evercore

by · The Markets Daily

Evercore began coverage on shares of Kestra Medical Technologies (NASDAQ:KMTS – Free Report) in a research report released on Tuesday, MarketBeat reports. The brokerage issued an outperform rating and a $34.00 target price on the stock.

KMTS has been the topic of a number of other research reports. Wolfe Research set a $30.00 price objective on shares of Kestra Medical Technologies in a report on Wednesday, July 15th. BTIG Research reiterated a “buy” rating and set a $32.00 price target on shares of Kestra Medical Technologies in a research report on Tuesday, September 15th. Wall Street Zen lowered Kestra Medical Technologies from a “hold” rating to a “sell” rating in a research note on Saturday, September 12th. Piper Sandler restated an “overweight” rating on shares of Kestra Medical Technologies in a report on Tuesday, September 15th. Finally, JPMorgan Chase & Co. started coverage on Kestra Medical Technologies in a report on Monday, August 10th. They issued an “overweight” rating and a $30.00 price target on the stock. Five analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Kestra Medical Technologies presently has a consensus rating of “Moderate Buy” and an average target price of $29.00.

View Our Latest Report on KMTS

Kestra Medical Technologies Trading Up 3.7%

NASDAQ:KMTS opened at $28.32 on Tuesday. Kestra Medical Technologies has a 1 year low of $17.34 and a 1 year high of $30.00. The company has a current ratio of 4.69, a quick ratio of 4.69 and a debt-to-equity ratio of 0.33. The stock has a fifty day moving average price of $26.42 and a two-hundred day moving average price of $23.79.

Kestra Medical Technologies (NASDAQ:KMTS – Get Free Report) last posted its quarterly earnings results on Monday, September 14th. The company reported ($0.75) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.61) by ($0.14). The company had revenue of $30.97 million for the quarter. Kestra Medical Technologies had a negative return on equity of 63.83% and a negative net margin of 140.43%. As a group, equities research analysts forecast that Kestra Medical Technologies will post -2.45 earnings per share for the current fiscal year.

Insider Activity

In other Kestra Medical Technologies news, insider Brian Webster sold 51,900 shares of the company’s stock in a transaction dated Tuesday, August 4th. The shares were sold at an average price of $24.52, for a total value of $1,272,588.00. Following the sale, the insider owned 475,215 shares of the company’s stock, valued at $11,652,271.80. This represents a 9.85% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Alfred J. Ford, Jr. sold 13,015 shares of the stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $23.90, for a total transaction of $311,058.50. Following the completion of the sale, the insider owned 105,839 shares in the company, valued at $2,529,552.10. This represents a 10.95% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 361,928 shares of company stock worth $9,158,873 in the last three months. Company insiders own 5.30% of the company’s stock.

Hedge Funds Weigh In On Kestra Medical Technologies

Several hedge funds have recently bought and sold shares of KMTS. Corient Private Wealth LP raised its holdings in shares of Kestra Medical Technologies by 284.2% in the second quarter. Corient Private Wealth LP now owns 60,614 shares of the company’s stock worth $1,542,000 after acquiring an additional 44,839 shares during the last quarter. Sei Investments Co. increased its position in Kestra Medical Technologies by 22.6% during the 1st quarter. Sei Investments Co. now owns 237,116 shares of the company’s stock worth $4,726,000 after purchasing an additional 43,753 shares in the last quarter. Spartan Wealth Advisory Services LLC purchased a new stake in Kestra Medical Technologies during the 1st quarter worth about $603,000. Bank of New York Mellon Corp raised its stake in Kestra Medical Technologies by 47.2% in the 1st quarter. Bank of New York Mellon Corp now owns 70,113 shares of the company’s stock valued at $1,397,000 after purchasing an additional 22,471 shares during the last quarter. Finally, Quantinno Capital Management LP acquired a new position in Kestra Medical Technologies in the 1st quarter valued at about $431,000.

Kestra Medical Technologies Company Profile

(Get Free Report)

Kestra Medical Technologies, Inc is a medical technology company focused on developing and commercializing wearable solutions for patients at risk of sudden cardiac arrest. Its primary product is the ASSURE wearable cardioverter defibrillator, a wearable device designed to continuously monitor a patient’s heart rhythm and deliver a therapeutic shock when clinically necessary.

The company’s platform combines cardiac monitoring, arrhythmia detection and defibrillation capabilities in a wearable system intended for use outside the hospital.

Further Reading